Get notified when NVNO files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Fda Not-approvable Letter For Venovalve (new) — The FDA has declined to approve the company's lead product, creating significant regulatory uncertainty.
- Nasdaq Minimum Bid Price Deficiency (new) — The company is at risk of delisting from Nasdaq if it cannot regain compliance with the minimum bid price rule.
enVVeno Medical files to sell up to $50M in stock via at-the-market offering after FDA rejects lead product
Filed October 30, 2025 · ~2 min read
Key Changes
-
high
enVVeno Medical may sell up to $50 million of common stock from time to time through Ladenburg at market prices, with no minimum offering amount required.
The Offering verify on EDGAR → -
high
The company's last reported sale price was $0.7188 per share on October 29, 2025, and selling the full $50 million at that price would issue up to 69.6 million new shares, increasing total shares outstanding to up to 89.8 million.
The Offering verify on EDGAR → -
high
Net proceeds are intended primarily for continued development of VenoValve and enVVe, with the remainder for general corporate purposes including potential acquisitions.
Use of Proceeds verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (SPWH 10-Q) is open in full — no account needed.
Partner
Trade NVNO commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify